Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
The Lancet. Oncology（2023）
摘要
Seagen and Merck & Co.
更多查看译文
关键词
colorectal cancer,metastatic colorectal cancer,trastuzumab,chemotherapy-refractory,wild-type,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要